India and Brazil are intensifying efforts to boost bilateral pharmaceutical trade and cooperation, with senior industry and regulatory officials from both countries exploring avenues to enhance market access, regulatory alignment and strategic partnerships.
At a recent India–Brazil Healthcare Business Gateway meeting convened by the government-backed export body Pharmexcil, representatives from Indian drug manufacturers, Brazilian healthcare executives and officials from Brazil’s regulatory authority ANVISA discussed ways to streamline market entry for Indian medicines, particularly in specialty medicines, oncology drugs, biosimilars and hospital-grade therapies.
Brazil has emerged as a fast-growing destination for Indian pharmaceuticals, accounting for around $778 million in exports in FY 2025 and registering strong year-on-year growth. During April–January of FY 2026, exports to Brazil reached approximately $740 million, significantly higher than the previous year, underscoring rising demand.
Officials highlighted that enhanced regulatory engagement, better compliance with local standards and stronger public healthcare supply linkages could help Indian firms expand their footprint in Brazil’s market, including small and medium-sized pharmaceutical exporters keen to scale up their presence.
Beyond direct trade, New Delhi and Brasília have also signed MoUs on MSME cooperation and pharmaceutical regulation, aimed at improving information sharing, regulatory alignment and broader collaboration in healthcare and medical products.
The move comes amid wider momentum in India-Brazil economic relations, with both countries targeting deeper trade ties and higher bilateral trade volumes, including pharmaceutical products as a key growth segment.
Stakeholders say that sustained engagement on regulatory pathways and local partnerships will be crucial to realising long-term export growth and cooperation, making Brazil an increasingly attractive market for Indian drugmakers.